Purchase Order VA5801N3839
- Not listed
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the provision of the Provant Therapy System and related rental services. The contract has a ceiling value of $7,142.85 and was awarded on February 18, 2011, with a completion date of March 18, 2011. The Provant Therapy System is a patented, noninvasive regenerative medicine product indicated for the palliative treatment of...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a noninvasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and was awarded on May 24, 2011, with a completion date of June 24, 2011....
- This is a $3,645.14 firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a noninvasive regenerative medicine product. The contract is not set-aside and was awarded under Regenesis Biomedical's existing GSA Schedule 65-II-A contract for medical equipment and supplies. The Provant Therapy System is indicated for palliative treatment of post-operative pain and edema, and Regenesis Biomedical appears to be the...
- This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a privately held medical technology company. The $4,820.98 contract is for the Provant Therapy System, a noninvasive regenerative medicine product developed and patented by Regenesis Biomedical. The Provant Therapy System is indicated for the palliative treatment of post-operative pain and edema. The contract has an ultimate completion date of March 16, 2011. Regenesis...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a for-profit medical technology company. The $4,820.98 contract is for the Provant Therapy System, a patented non-invasive regenerative medicine product indicated for post-operative pain and edema treatment. The contract was awarded under Regenesis Biomedical's existing General Services Administration (GSA) Schedule 65-II-A contract for medical equipment and...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the Provant Therapy System. The contract, valued at $4,992.40, is for the provision of the Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract is not associated with a set-aside program and appears to be part of Regenesis...
- This is a firm fixed price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company, for the Provant Therapy System. The contract, which has a ceiling value of $7,142.85, is for the palliative treatment of post-operative pain and edema. The contract was awarded on November 3, 2010, with a completion date of December 3, 2010. No set-aside was used for this award. Regenesis Biomedical Inc. has been registered in...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical device manufacturer. The contract, valued at $3,645.14, is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract does not have a set-aside designation. Regenesis Biomedical Inc. is the prime contractor and...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a medical technology company. The contract is for the provision of Regenesis Biomedical's Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract has a ceiling value of $7,231.47 and a completion date of June 24, 2011. There is no set-aside designation...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc., a private medical technology company. The $3,698.05 contract is for the provision of Regenesis Biomedical's proprietary Provant Therapy System, a non-invasive regenerative medicine product indicated for the palliative treatment of post-operative pain and edema. The contract was not set aside for any preferential contracting vehicle. Regenesis Biomedical has been...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Regenesis Biomedical Inc. for the Provant Therapy System, a non-invasive regenerative medicine product. The contract has a ceiling value of $3,675.14 and a completion date of August 12, 2011. Regenesis Biomedical is the prime contractor and manufacturer of the Provant Therapy System, which is indicated for the palliative treatment of post-operative pain and edema. The contract was awarded through the VA's GSA Schedule 65-II-A for medical equipment and supplies, and does not use any set-aside designations. The contract provides for the purchase and/or rental of the Provant Therapy System devices by VA healthcare facilities across different regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 7/12/11 |